Observational studyScientific reports2025
Impact of CNS medication burden and drug interactions on delirium in patients with advanced cancer: a multicenter prospective observational study.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cannabinoids and opioid consumption in cancer pain: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Potentially Clinically Relevant Drug-Drug Interactions in Oncology Patients Receiving Chronic Opioid Therapy: Prevalence and Associated Factors.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Delirium is a common neuropsychiatric complication in patients with advanced cancer. Central nervous system (CNS)-active medications are established risk factors for delirium; however, these patients often require polypharmacy for symptom management, resulting in a high medication burden and increased risk of drug-drug interactions (DDIs). The impact of CNS medication burden and DDIs on delirium remains unclear. This multicenter, prospective observational study examined the association between CNS medication burden, measured using the CNS standardized daily dose (SDD), DDIs, and delirium incidence, duration, and mortality in hospitalized patients with advanced cancer. Among 190 patients, 20% developed delirium. CNS SDD was associated with delirium risk (adjusted OR [aOR]: 1.04, 95% CI: 1.0004-1.08). In categorical analyses, patients with a CNS SDD ≥ 10 had a significantly higher risk of delirium (aOR: 4.29, 95% CI: 1.33-15.47). Potential DDIs increasing exposure to delirium-risk medications had an aOR of 4.14 (95% CI: 0.96-17.41). Although neither CNS SDD nor DDIs affected delirium duration, opioid burden was associated with increased mortality. CNS medication burden and DDIs may be important factors for delirium and clinical outcomes. These findings underscore the need for medication optimization and proactive DDI monitoring to reduce the risk of delirium and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.